Moake J L, Weinstein M J, Troll J H, Chute L E, Colannino N M
Blood. 1983 Jun;61(6):1163-73.
The predominant procoagulant factor VIII (VIII:C) form in normal human plasma containing various combinations of anticoagulants and serine/cysteine protease inhibitors is a protein with mol wt 2.6 +/- 0.2 X 10(5). This protein can be detected by 125I-anti-VIII:C Fab binding and gel electrophoresis in the presence and absence of sodium dodecylsulfate (SDS) and is distinct from the subunit of factor VIII/von Willebrand factor (VIII:vWF) multimers. No larger VIII:C form is present in plasma from patients with severe congenital deficiencies of each of the coagulation factors, other than VIII:C. The mol wt approximately 2.6 X 10(5) VIII:C form is, therefore, likely to be the in vivo procoagulant form of VIII:C, rather than a partially proteolyzed, partially activated derivative of a larger precursor. About 60% of this procoagulant mol wt approximately 2.6 X 10(5) VIII:C form in plasma is present in noncovalent complexes with larger VIII:vWF multimers, which attach reversibly to platelet surfaces in the presence of ristocetin. This VIII:vWF-bound protein of mol wt approximately 2.6 X 10(5) may be the plasma procoagulant form of VIII:C which, after proteolytic activation, accelerates the IXa-mediated cleavage and activation of X postulated to occur on platelet surfaces.
在含有各种抗凝剂和丝氨酸/半胱氨酸蛋白酶抑制剂组合的正常人血浆中,主要的促凝血因子VIII(VIII:C)形式是一种分子量为2.6±0.2×10⁵的蛋白质。这种蛋白质可通过¹²⁵I-抗VIII:C Fab结合以及在有无十二烷基硫酸钠(SDS)存在的情况下进行凝胶电泳来检测,并且与因子VIII/血管性血友病因子(VIII:vWF)多聚体的亚基不同。除VIII:C外,患有其他凝血因子严重先天性缺陷的患者血浆中不存在更大的VIII:C形式。因此,分子量约为2.6×10⁵的VIII:C形式可能是VIII:C在体内的促凝血形式,而不是更大前体的部分蛋白水解、部分活化的衍生物。血浆中这种分子量约为2.6×10⁵的促凝血VIII:C形式约60%以与更大的VIII:vWF多聚体形成的非共价复合物形式存在,并在瑞斯托菌素存在的情况下可逆地附着于血小板表面。这种分子量约为2.6×10⁵且与VIII:vWF结合的蛋白质可能是VIII:C的血浆促凝血形式,在蛋白水解激活后,加速假定在血小板表面发生的由IXa介导的X的裂解和激活。